Gene therapy developer RegenXBio, backed by investors including GlaxoSmithKline, has so far raised more than $110m in venture funding.
RegenXBio, a US-based gene therapy developer that counts pharmaceutical firm GlaxoSmithKline (GSK) among its investors, has filed for an initial public offering on Nasdaq that could raise up to $100m.
Co-founded by biomedical research company Foxkiser, University of Pennsylvania and RegenXBio’s chief scientific advisor James M. Wilson, the company is developing drugs for a variety of disorders based on its adeno-associated virus gene therapy delivery platform.
The platform is responsible for five treatments being developed internally and another 18 externally…
